RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
–
Operating margin
-94.6%−17.4 pts over 5 years
Net margin
-113.8%−41.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +104.5% | +14.8% | +2.0% | +36.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -33.3% | -26.9% | -107.0% | |
| Return on assets | -32.0% | -18.4% | -42.2% | |
| Current ratio | 9.66 | 6.52 | 2.38 | |
| Interest coverage | – | -154.6× | -3.6× | |
| Capex to revenue | 177.6% | 17.4% | 1.4% | |
| Diluted shares | 26M | 37M | 52M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Regenxbio generated $941.86M from operations and spent $129.71M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$941.86M
Used
$129.71M
Capital expenditure$129.71M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-113.8%
×Asset turnover0.37×
×Equity multiplier2.54×
=Return on equity, FY2025-107.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -113.8% | 0.37× | 2.54× | -107.0% |
| FY2024 | -272.5% | 0.16× | 1.82× | -79.5% |
| FY2023 | -292.0% | 0.13× | 1.70× | -63.7% |
| FY2022 | -248.7% | 0.12× | 1.52× | -43.8% |
| FY2021 | 27.2% | 0.52× | 1.60× | 22.4% |
| FY2020 | -72.0% | 0.26× | 1.46× | -26.9% |
| FY2019 | -268.9% | 0.07× | 1.09× | -19.8% |
| FY2018 | 45.7% | 0.59× | 1.07× | 28.9% |
| FY2017 | -704.0% | 0.06× | 1.08× | -42.4% |
| FY2016 | -1372.1% | 0.02× | 1.04× | -33.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$193.88M
- Cash generatingOperating cash flow above zero-$123.96M
- Return on assets improvedROA up on the prior year-39.6% → -41.6%
- Earnings backed by cashOperating cash flow above net income-$123.96M vs -$193.88M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.69 → 2.38
- No dilutionShare count did not rise50M → 52M
- Gross margin improvedGross margin up on the prior year59.72% → –
- More efficientAsset turnover rose0.15 → 0.37